Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
Secondary analysis of an RCT (n=10,061) found a reduced rate of incident total hip or knee replacement for those given canakinumab every 3 months vs placebo [HR 0.60, (95%CI 0.38-0.95), 0.53 (0.33-0.84) and 0.60 (0.38-0.93) for 50 mg, 100 mg and 300 mg vs placebo respectively]
Source:
Annals of Internal Medicine
SPS commentary:
An editorial review this new evidence, noting that this secondary analysis of the CANTOS trial presents intriguing results that may offer promise for IL-1 inhibition as a treatment. Further studies should evaluate the importance of elevated CRP levels as a factor affecting response to treatment, and to include more women to better reflect the osteoarthritis population.